Do you want to skip to content? Skip to content
Convatec Group Contact Us България България Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Österreich Österreich Schweiz (Deutsch) Schweiz (Deutsch) Deutschland Deutschland Ελλάδα Ελλάδα United Kingdom United Kingdom Ireland Ireland España España Eesti Eesti Suomi Suomi Suisse (Français) Suisse (Français) France France Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Italia Italia Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta Norge Norge België België Nederland Nederland Polska Polska Portugal Portugal România România Slovensko Slovensko Slovenija Slovenija Srbija Srbija Sverige Sverige Türkiye Türkiye Україна Україна Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق New Zealand New Zealand 日本 日本 Australia Australia India India Malaysia Malaysia Singapore Singapore 대한민국 대한민국 中国大陆 中国大陆 中国台湾 中国台湾 ไทย ไทย Indonesia Indonesia Việt Nam Việt Nam Philippines Philippines Hong Kong SAR China (English) Hong Kong SAR China (English) 中国香港特别行政区 (中文(简体,中国香港特别行政区)) 中国香港特别行政区 (中文(简体,中国香港特别行政区))
False /oidc-signin/en-us/ Convatec Group Contact Us България България Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Österreich Österreich Schweiz (Deutsch) Schweiz (Deutsch) Deutschland Deutschland Ελλάδα Ελλάδα United Kingdom United Kingdom Ireland Ireland España España Eesti Eesti Suomi Suomi Suisse (Français) Suisse (Français) France France Hrvatska Hrvatska Magyarország Magyarország Ísland Ísland Italia Italia Lietuva Lietuva Latvija Latvija Северна Македонија Северна Македонија Malta Malta Norge Norge België België Nederland Nederland Polska Polska Portugal Portugal România România Slovensko Slovensko Slovenija Slovenija Srbija Srbija Sverige Sverige Türkiye Türkiye Україна Україна Brasil Brasil United States (English) United States (English) Estados Unidos (Español) Estados Unidos (Español) Argentina Argentina Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Ecuador Ecuador México México Perú Perú Belize Belize Guyana Guyana Jamaica Jamaica Venezuela Venezuela Costa Rica Costa Rica Curaçao Curaçao República Dominicana República Dominicana Guatemala Guatemala Honduras Honduras Nicaragua Nicaragua Panamá Panamá Puerto Rico Puerto Rico Suriname Suriname El Salvador El Salvador الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين مصر مصر ישראל ישראל ایران ایران الأردن الأردن عُمان عُمان قطر قطر پاکستان پاکستان لبنان لبنان الكويت الكويت المملكة العربية السعودية المملكة العربية السعودية Suid-Afrika Suid-Afrika العراق العراق New Zealand New Zealand 日本 日本 Australia Australia India India Malaysia Malaysia Singapore Singapore 대한민국 대한민국 中国大陆 中国大陆 中国台湾 中国台湾 ไทย ไทย Indonesia Indonesia Việt Nam Việt Nam Philippines Philippines Hong Kong SAR China (English) Hong Kong SAR China (English) 中国香港特别行政区 (中文(简体,中国香港特别行政区)) 中国香港特别行政区 (中文(简体,中国香港特别行政区))

Neurogenic Bladder - Multiple Sclerosis

Our professional content originates from Melissa Fulton, RN, BSN, MSN, FNP, APRN-C, Certified MS Specialist, and other healthcare contributors.

Multiple Sclerosis or MS is a disease in which the immune system attacks the brain, spinal cord, and optic nerves resulting in the destruction of myelin (the protective covering of nerves). Think of it as an electrical cord losing its outer covering and the inner wires are exposed. The result can be an interruption in appropriate signals in the nervous system.

diagram ;

The illustration on the left represents a healthy neuron in contrast to the nerve on the right that is affected by MS.

When the nerves that control urination are affected, it can result in either urinary retention (incomplete emptying of the bladder) or overactive bladder (bladder spasms).

Over 80% of those living with MS will experience bladder issues1 and symptoms may include:

  • Frequency, urgency and/or hesitancy of urination
  • Frequent nighttime urination
  • Incontinence
  • Incomplete bladder emptying

Treatment Options

Although there is no cure for MS, most bladder issues related to MS are manageable and treatable. Treatment is based on presenting symptoms but may include:

Lifestyle modifications include bladder training, diet modification, and adequate fluid intake. Reducing fluid intake in the evening can help manage nocturia (urinating at night) symptoms. Caffeine-free, noncarbonated fluids without aspartame are preferred because they are least irritating to the bladder.

Anticholinergic drugs block the action of the chemical messenger acetylcholine. Acetylcholine sends signals to your brain that trigger bladder contractions. An excess of acetylcholine in your system may result in an overactive bladder. Beta 3 Agonists work to relax the bladder muscle and can increase the storage capacity. With any increase in bladder volume, the urinary stream may be stronger and allow the bladder to empty more to completion.

A physical therapist specifically trained in the pelvic floor may use a variety of techniques and exercises to manage overactive bladders. Strategies that may assist in strengthening and controlling the muscles used during urination include biofeedback, neuromuscular stimulation, and daily home exercises.

Additional treatments for overactive bladder may include Percutaneous Tibial Nerve Stimulations (PTNS)
and InterStim

  • PTNS is a 30-minute treatment performed weekly for 12 weeks by inserting a needle electrode
    into the tibial nerve located superior to the ankle. The electrode transmits a signal to the sacral
    plexus. The bundle of nerves of the sacral plexus controls the bladder and pelvic floor muscles.
    Providing stimulation to this nerve appears to down regular the bladder.
  • InterStim is a small device that can be surgically placed under the skin. It stimulates the sacralnerves again down regulating the nerve endings with the goal to treat both overactive bladder and urinary retention.

Intermittent Self-Catheterization may be recommended for difficulty emptying the bladder. Catheterization is when a catheter is inserted into the urethra to empty the bladder and then removed. Self-Catheterizing one or more times per day can help control bladder leakage, urgency and frequency, and nighttime urination in people who cannot completely empty their bladder on their own.

Since there is no cure for MS, it is good to know that there are many treatment options for neurogenic bladder symptoms. Bladder health can be crucial for overall health and quality of life. Available treatment options are effective for managing most symptoms patients experience with Neurogenic Bladder due to MS.

References: 1. https://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms/Bladder-Dysfunction

Related Articles

Related Articles

Catheter Selection

When navigating intermittent catheter selection for patients, finding a product that will help them stay compliant to their prescribed cathing regimen is key. To ensure optimized patient outcomes, you'll want to consider: Comfort during insertion and removal, UTI prevention and maintaining activity levels and quality of life..

Read more

Related Articles

Teaching Patients Self-Catheterization

Our education and training equip us well to perform intermittent catheterization on a patient. However, teaching a patient to perform self-intermittent catheterization (SIC) requires a different skill set. Urology healthcare professionals are comfortable discussing what most patients consider to be very private matters...

Read more

Related Articles

Urology Retention - Introduction

In general, urinary retention is defined as the inability for the bladder to empty to completion. It may be a chronic or an acute condition experienced by men and women due to several health problems – including structural and neurological issues. There is a lack of standardized guidance on the volume of urine retained in the bladder that constitutes urinary retention...

Read more

Enroll your patients in me+™ or Request product samples

The me+™ support program offers your patients tools to help make their life as a catheter user completely their own. Enroll your intermittent catheter patients in me+™ or request free product samples. Empower your patients to experience the latest technology and discover answers to the most commonly asked cathing questions.

From a wide range of product solutions to educational tools and resources, we're here to help support you and your patients.

Speak with a member of the me+™ support team today.

Call 1-800-422-8811 (M-F, 8:30 AM-7:00 PM ET).

Contact Us

You are leaving convatec.com

This Internet site may provide links or references to other sites but Convatec have no responsibility for the content of such other sites and shall not be liable for any damages or injury arising from that content. Any links to other sites are provided as merely a convenience to the users of this Internet site.

Do you wish to continue?